RT Journal Article
SR Electronic
T1 Towards a gene-level map of resilience to genetic variants associated with autism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.12.21251621
DO 10.1101/2021.02.12.21251621
A1 Thomas Rolland
A1 Freddy Cliquet
A1 Richard J.L. Anney
A1 Nicolas Traut
A1 Alexandre Mathieu
A1 Guillaume Huguet
A1 Claire S. Leblond
A1 Elise Douard
A1 Frédérique Amsellem
A1 Simon Malesys
A1 Anna Maruani
A1 Roberto Toro
A1 Alan Packer
A1 Wendy K. Chung
A1 Sébastien Jacquemont
A1 Richard Delorme
A1 Thomas Bourgeron
YR 2021
UL http://medrxiv.org/content/early/2021/03/06/2021.02.12.21251621.abstract
AB While over 100 genes are now significantly associated with autism spectrum disorders (ASD), the penetrance of the variants affecting these genes remains poorly understood. Here, we quantified the prevalence of rare loss-of-function (LoF) mutations affecting 156 genes robustly associated with ASD (SPARK genes) using genetic data from more than 10,000 individuals with ASD and 100,000 undiagnosed individuals. We then investigated the clinical, brain imaging and genetic profiles of individuals heterozygous for these rare deleterious variants who were not diagnosed with ASD. These “resilient” individuals, observed in less than 1% of the general population, were equally distributed among males and females, but displayed low polygenic scores for ASD compared to LoF heterozygotes diagnosed with ASD. The interplay between rare and common variants may therefore contribute to the clinical profiles of the individuals carrying LoF in genes associated with ASD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from SFARI (number 240059), the Institut Pasteur, the Bettencourt-Schueller Foundation, Universite de Paris, the Conny-Maeva Charitable Foundation, the Cognacq Jay Foundation, the Eranet-Neuron (ALTRUISM), the GenMed Labex, AIMS-2-TRIALS which received support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 and the Inception program (Investissement d Avenir grant ANR-16-CONV-0005). This project has received funding from the European Union Horizon 2020 research and innovative program CANDY under grant agreement No 847818.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institut Pasteur IRB (IRB00006966) exempted this study review according to the 45CFR46 provisions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhole-exome and SNP genotyping data from the SSC and SPARK cohorts can be obtained by applying at SFARI Base (https://www.sfari.org/resource/sfari-base/). The UK-Biobank whole-exome, SNP genotyping and brain imaging data can be obtained by applying at the UK-Biobank database (https://www.ukbiobank.ac.uk/). The human neurodevelopmental transcriptome dataset is available on the BrainSpan database (http://www.brainspan.org). Functional annotations can be obtained from SynGO (https://syngoportal.org/) and Gene Ontology (http://current.geneontology.org/annotations/goa_human.gaf.gz). Electronic health records and healthcare claims data used in the present study for the UK-Biobank individuals are not publicly available due to patient privacy concerns. Prevalence and risk measures can be visualized and downloaded on https://genetrek.pasteur.fr/. https://www.sfari.org/resource/sfari-base/ http://www.brainspan.org https://syngoportal.org/ http://current.geneontology.org/annotations/goa_human.gaf.gz